You are here

durvalumab

AstraZeneca’s shares spike on positive PhIII lung cancer data — but it’s not MYSTIC

AstraZeneca’s shares spike on positive PhIII lung cancer data — but it’s not MYSTIC

Endpoints

clinical trials

non-small cell lung cancer

Flag link:

Checkpoint inhibitors set to face off in bladder cancer

Checkpoint inhibitors set to face off in bladder cancer

BioPharma Dive

Bristol-Myers Squibb

Flag link:

AZ chief: Durvalumab's ready for a 'marketing battle' against I-O heavyweights Opdivo, Keytruda

AZ chief: Durvalumab's ready for a 'marketing battle' against I-O heavyweights Opdivo, Keytruda

Fierce Pharma

immuno-oncology

Bristol-Myers Squibb

Flag link:

AstraZeneca angles for more competitive position in immuno-oncology

AstraZeneca angles for more competitive position in immuno-oncology

BioPharma Dive

immuno-oncology

Flag link:

AstraZeneca delays PD-L1 data in rejig of phase 3 program

AstraZeneca delays PD-L1 data in rejig of phase 3 program

Fierce Biotech

clinical trials

Flag link:

Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?

Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?

Endpoints

Flag link:

Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

Market Realist

Bristol-Myers Squibb

Flag link:

Here's Why AstraZeneca Dipped 14.2% in October

Here's Why AstraZeneca Dipped 14.2% in October

Motley Fool

Flag link:

FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs

FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs

Endpoints

clinical trials

head and neck cancer

Flag link:

Amgen's Biosimilar Approval And Astra's Anti-PD-L1 Data

Amgen's Biosimilar Approval And Astra's Anti-PD-L1 Data

Seeking Alpha

Flag link:

AstraZeneca Rides High, Fueled by Brexit, Bristol-Myers Failure

AstraZeneca Rides High, Fueled by Brexit, Bristol-Myers Failure

Yahoo/Bloomberg

Bristol-Myers Squibb

Flag link:

AstraZeneca gets a boost from durvalumab PhIII chatter as pipeline wear and tear starts to show

AstraZeneca gets a boost from durvalumab PhIII chatter as pipeline wear and tear starts to show

Endpoints

Flag link:

AstraZeneca wins FDA breakthrough status for key cancer drug

AstraZeneca wins FDA breakthrough status for key cancer drug

Yahoo/Reuters

breakthrough status

Flag link:

AstraZeneca's cancer checkpoint combo looks promising in small lung cancer study

AstraZeneca's cancer checkpoint combo looks promising in small lung cancer study

Fierce Biotech

metastatic non-small cell lung cancer

Flag link:

AstraZeneca hit with setback as durvalumab falls further behind on lung cancer

AstraZeneca hit with setback as durvalumab falls further behind on lung cancer

Fierce Biotech

PDL-1 inhibitors

Flag link:

AstraZeneca cancer drug may not be so fast getting to market

AstraZeneca cancer drug may not be so fast getting to market

Yahoo/Reuters

Flag link:

AstraZeneca halts a pair of lung cancer trials over a safety scare

AstraZeneca halts a pair of lung cancer trials over a safety scare

Fierce Biotech

clinical trials

Flag link:

AstraZeneca ties up with little Mirati on another PD-L1 combo trial

AstraZeneca ties up with little Mirati on another PD-L1 combo trial

Fierce Biotech

PD-1 inhibitors

Mirati Therapeutics

Flag link: